J. Deanfield Et Al. , "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.," Lancet (London, England) , vol.404, no.10454, pp.773-786, 2024
Deanfield, J. Et Al. 2024. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.. Lancet (London, England) , vol.404, no.10454 , 773-786.
Deanfield, J., Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., Ryan, D., ... Lingvay, I.(2024). Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.. Lancet (London, England) , vol.404, no.10454, 773-786.
Deanfield, John Et Al. "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.," Lancet (London, England) , vol.404, no.10454, 773-786, 2024
Deanfield, John Et Al. "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.." Lancet (London, England) , vol.404, no.10454, pp.773-786, 2024
Deanfield, J. Et Al. (2024) . "Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.." Lancet (London, England) , vol.404, no.10454, pp.773-786.
@article{article, author={John Deanfield Et Al. }, title={Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.}, journal={Lancet (London, England)}, year=2024, pages={773-786} }